93.46MMarket Cap-8297P/E (TTM)
6.230High6.000Low12.42KVolume6.200Open6.220Pre Close76.49KTurnover0.11%Turnover RatioLossP/E (Static)15.22MShares10.69052wk High2.65P/B71.60MFloat Cap3.21052wk Low--Dividend TTM11.66MShs Float10.690Historical High--Div YieldTTM3.70%Amplitude3.210Historical Low6.156Avg Price1Lot Size
Coya Therapeutics Stock Forum
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on...
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protectionfor the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).
This combination aims to enhance regulatory T cell function and may offer a mul...
Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
Benzinga· 2 mins ago
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combinatio...
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS p...
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and...
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (Addf)
NEWS
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Serum 4-HNE levels in ALS patients correlate with disease progression and survival, with higher levels indicating faster progression and shorter survival. The ROC analysis shows 100% sensitivity for a 21-month survival threshold, making it a potential biomarker for ALS. The presentation at the Johnson Center Symposium highlighted the predictive value of 4-HNE in as...
No comment yet